1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
euglena Co., Ltd.

euglena Co., Ltd.

333.00
JPY
0.00
(0.00%)
46.31BMarket Cap
Nov 13Next Earn
euglena Co., Ltd.
TSE:2931
(Tokyo Stock Exchange)

Recent

price

333.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
JPY
23.99
29.43
32.13
40.23
73.76
134.89
166.75
178.15
152.88
143.32
231.08
395.91
398.74
349.13
369.17
- -
Revenue per Share
4.21
3.66
7.41
1.56
5.85
8.18
9.44
-14.7
-107.25
-16
-24.12
-23.83
-22.75
-4.77
-5.9
- -
Basic EPS, GAAP
5.11
1.03
1.24
-2.37
3.81
-2.06
-44.44
-52.78
-3.17
-17.34
11.56
3.82
-0.3
14.03
33.66
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
14.63
17.6
37.36
133.96
154.74
162.54
185.67
185.63
116.62
100.72
202.19
171.12
172.57
232.45
226.67
237.84
Book Value per Share
14.6
17.54
36.94
133.13
140.4
147.53
166.37
141.53
98.86
83.97
-89.9
-94.36
-64.47
-13.64
-0.04
22.63
Tangible Book Value per Share
49
54
65
76
80
82
83
85
91
93
101
112
117
136
136
138
Basic Weighted Avg Shares
1,166
1,586
2,092
3,046
5,924
11,103
13,887
15,175
13,968
13,317
23,292
44,392
46,482
47,618
50,370
- -
Sales/Revenue/Turnover
25.25
19.41
8.44
4.67
8.04
6.25
6.85
-9.09
-53.41
-13.57
-17.01
-7.79
-3.15
0.63
6.2
- -
Operating Margin (%)
- -
13
35
67
170
320
462
766
957
719
1,408
3,175
2,970
3,598
3,347
- -
Depreciation Expense
205
197
483
118
470
673
786
-1,252
-9,799
-1,487
-2,431
-2,672
-2,652
-650
-805
- -
Net Income, GAAP
34.58
39.33
17.78
38.44
38.56
27.62
35.18
- -
- -
- -
- -
- -
- -
- -
72.15
- -
Effective Tax Rate (%)
17.57
12.45
23.07
3.88
7.93
6.06
5.66
-8.25
-70.15
-11.16
-10.44
-6.02
-5.71
-1.37
-1.6
- -
Profit Margin (%)
960
1,003
2,134
6,691
7,212
9,743
8,936
6,280
8,713
7,631
12,985
7,418
12,160
18,054
19,459
5,241
Working Capital
- -
- -
199
22
80
63
1,125
3,390
3,191
3,217
23,597
19,503
21,772
21,770
23,732
5,991
LT Debt
971
1,169
2,569
10,445
12,701
13,423
15,655
15,905
10,834
9,387
22,187
19,353
20,213
32,113
28,527
31,568
Total Equity
- -
16.02
7.1
1.31
2.45
3.71
3.98
- -
- -
- -
- -
- -
- -
- -
1.49
- -
Return on Invested Capital (%)
- -
18.45
24.48
1.8
4.1
5.15
5.2
- -
- -
- -
- -
- -
- -
- -
-3.51
- -
Return on Capital (%)
- -
18.45
25.82
1.82
4.06
5.16
5.41
-7.94
-73.32
-14.72
-15.41
-12.87
-13.41
-2.5
-2.57
- -
Return on Common Equity (%)

Capital Structure

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
ST Debt
4,406
- -
17,070
LT Borrowings
22,487
- -
5,978
LT Finance Leases
8
- -
13
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
136
139
140
Market Capitalization
73,733
55,840
46,314

Working Capital

JPY

•

in mil. unless spec.
Jun'24
Mar'26
Jun'26
Total Current Assets
29,196
- -
30,948
Cash, Cash Equivalents & STI
19,091
- -
17,174
Accounts Receivable, Net
4,152
- -
4,807
Inventories
4,363
- -
4,483
Total Current Liabilities
12,278
- -
25,707
Payables & Accruals
- -
- -
- -
ST Debt
4,406
- -
17,070
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.44%
35.15%
-11.17%
Free Cash Flow
-345.66%
-1,153.88%
140.09%
Net Income, GAAP
41.95%
4.21%
23.85%
Sales/Revenue/Turnover
28.76%
35.68%
5.78%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
11,154
12,495
- -
- -
47,618
2025
- -
- -
- -
- -
50,370
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.49
-3.36
- -
- -
-4.77
2025
- -
- -
- -
- -
-5.9
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Euglena Co., Ltd. is a Japan-based biotechnology company specializing in the research, development, production, and sale of microalgae-derived products. Its core offerings include functional foods and supplements; cosmetics leveraging the unique properties of Euglena algae for skin health; and biofuels such as Sustainable Aviation Fuel (SAF) and Hydrotreated Vegetable Oil (HVO). The company operates through three main business segments: Healthcare, which focuses on planning and sales of food products and cosmetics using their proprietary microalgae cultivation; Biofuel, which is engaged in the development, production, and commercialization of next-generation biofuels and cultivation technology; and Other Businesses, including organic compound fertilizers, genetic analysis services, and agritech innovations. Euglena’s manufacturing base includes a production plant on Ishigaki Island, Okinawa, known for sustainable and nature-rich conditions. Founded in 2005 and headquartered in Minato-ku, Tokyo, Euglena continues to drive innovation in sustainable bio-product development. The company recently expanded its biofuel operations by increasing its equity stake to 15% in a Malaysian biorefinery joint venture alongside PETRONAS and Eni, targeting an annual handling capacity of approximately 100,000 kiloliters of biofuels, including SAF and HVO. This milestone advances Euglena toward commercialization expected by late 2028, with projected revenue of JPY 30 billion and significant profit contributions. Additionally, Euglena secured a joint research agreement with PETRONAS Research Sdn. Bhd. and demonstrated successful high-density tank cultivation scaling. In 2024, the company reported improved financial performance marked by a 2.4% increase in net sales and substantial EBITDA growth reflecting stronger cash flow management. Euglena’s strategy emphasizes sustainability and innovation to address nutritional, environmental, and energy challenges across Japan and globally in partnership with leading energy and biotech firms.